HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
At HTL Biotechnology, we put our expertise in biopolymers at the service of medical innovation. With 100% French-based production and the highest quality standards, we support laboratories worldwide in developing safe, effective, and sustainable therapeutic solutions.
Moments like these are essential to anticipate market evolutions and to continue building, together with our partners, the innovations of tomorrow.
Ophthalmic diseases affect millions of patients worldwide and demand innovative, reliable, and differentiating solutions. We strongly believe that biopolymers have the potential to transform how these conditions are treated.
By supporting hydration, ocular protection, and serving as vectors for innovative drug delivery strategies, these biomaterials are becoming essential allies for the therapies of tomorrow.
At ESCRS 2025, we shared our conviction: ophthalmology is entering a new era, and HTL Biotechnology is proud to contribute to this transformation alongside its partners.
Feel the difference with HTL Inside.
We’re pleased to share our second CSR report, highlighting the actions and commitments we carried out throughout 2024.
A Global Scientific Gathering Dedicated to Hyaluronic Acid Innovation.
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.